New findings reported from University of Reims describe advances in angiology
2009 JUL 6 - (NewsRx.com) -- According to a study from Reims, France, "Ibuprofen loaded embolization beads (IBU-BB) have been developed to reduce inflammation and pain following uterine artery embolization for the treatment of uterine fibroids. The present work has investigated the elution properties of IBU-BB in situ after embolization with Fourier Transform Infrared Microspectroscopy (FTIRMS)." "Twelve sheep underwent uterine artery embolization with IBU-BB (485 mM) or control unloaded beads. IBU concentration was determined inside the beads and in the tissue surrounding the beads using FTIRMS of uterine tissue sections sampled 24 h or 1 week after embolization. After 24 h, IBU concentration inside the bead was only 18.6 mM out of the 485 mM initially loaded (p < 0.0001, univariate sign test). The concentration in the tissue around the beads was 8 mM, which is well above the in vitro therapeutic levels (6 mc M). After one week the concentration of IBU had decreased to 4.9 mM in the beads (p = 0.0502, Mann Whitney) and no IBU was detected in the surrounding tissue. This work has demonstrated that IBU-BB can provide a sustained release of the anti-inflammatory drug over at least one week," wrote J. Namur and colleagues, University of Reims. The researchers concluded: "The in vivo elution properties of IBU-BB may be suitable to alleviate pain and inflammation after embolization." Namur and colleagues published the results of their research in the Journal of Controlled Release (Infrared microspectroscopy analysis of Ibuprofen release from drug eluting beads in uterine tissue. Journal of Controlled Release, 2009;135(3):198-202). For additional information, contact J. Namur, University of Reims Champagne Ardennes, MeDyC, CNRS, UMR 6237, Unite MeDIAN, 51 Rue Cognaq Jay, F-51096 Reims, France. The publisher of the Journal of Controlled Release can be contacted at: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands. Keywords: France, Reims, Angiology, Controlled Release, Drugs, Embolization, Fibroids, Ibuprofen, Inflammation, Pharmaceuticals, Therapy, Treatment, Uterine Artery, University of Reims. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
